Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLCJonathan W. Riess, Alexa B. Schrock, Philip J. Stephens et al.|Journal of Thoracic Oncology|2018Cited by 236
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 casesPhilip C. Mack, David R. Gandara, Kimberly C. Banks et al.|Cancer|2020Cited by 184
Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc’h, Darren A.E. Cross, Matthew J. Martin et al.|Molecular Cancer Therapeutics|2018Cited by 113
Bridging Tumor Genomics to Patient Outcomes Through an Integrated Patient-Derived Xenograft PlatformDavid R. Gandara, Edison T. Liu, Philip C. Mack et al.|Clinical Lung Cancer|2015Cited by 19